Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Toxoplasmosis, Cerebral; HIV Infections
Intervention: Pyrimethamine (Drug); Clindamycin (Drug)
Phase: N/A
Status: Completed
Sponsored by: Palo Alto Medical Foundation
Summary
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides
in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
Clinical Details
Official title: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Study design: Primary Purpose: Treatment
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions are excluded:
- Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal
meningitis) or other conditions (brain abscess) which would make treatment results
difficult to interpret due to concurrent infection, disease, or therapy.
Patients with other opportunistic infections or brain diseases are excluded.
Patients with AIDS and cerebral toxoplasmosis.
Locations and Contacts
Palo Alto Med Foundation, Palo Alto, California 94301, United States
Additional Information
Last updated: June 23, 2005
|